Evidence map›Paper›PMID 26965861›Full record

ArticleBioorganic & medicinal chemistry letters2016

D-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold.

Niyada Hin, Bridget Duvall, James F Berry, Dana V Ferraris, Rana Rais, Jesse Alt, Camilo Rojas, Barbara S Slusher, Takashi Tsukamoto

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Promising Application of D-Amino Acids toward Clinical Therapy.International journal of molecular sciences · 2022
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Niyada HinJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
Bridget DuvallJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
James F BerryJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
Dana V FerrarisJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA; Department of Chemistry, McDaniel College, 2 College Hill, Westminster, MD 21157, USA.
Rana RaisJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
Jesse AltJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
Camilo RojasJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA; Department of Molecular and Comparative Pathobiology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
Barbara S SlusherJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA.
Takashi TsukamotoJohns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA. Electronic address: ttsukamoto@jhmi.edu.
Johns Hopkins University · US

Funding

DAAO Inhibitors for the treatment of SchizophreniaR01MH091387 · NIMH · JOHNS HOPKINS UNIVERSITY · PI TSUKAMOTO, TAKASHI · 2011 to 2014
$2.1M
NIMH NIH HHS R01 MH091387NIMH NIH HHS R01MH091387
6 · The paper itself

Abstract

A series of 3-substituted 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives were designed and synthesized as a new class of d-amino acid oxidase (DAAO) inhibitors. Some of the newly synthesized derivatives showed potent inhibitory activity against human DAAO with IC50 values in the nanomolar range. Among them, 6-hydroxy-3-phenethyl-1,2,4-triazin-5(2H)-one 6b and 3-((6-fluoronaphthalen-2-yl)methylthio)-6-hydroxy-1,2,4-triazin-5(2H)-one 6m were found to be metabolically stable in mouse liver microsomes. In addition, compound 6b was found to be orally available in mice and able to enhance plasma d-serine levels following its co-administration with d-serine compared to the oral administration of d-serine alone.

Indexed as

AnimalsD-Amino-Acid OxidaseDose-Response Relationship, DrugEnzyme InhibitorsHumansMiceMicrosomes, LiverMolecular StructureSerineStructure-Activity RelationshipTriazines5-hydroxy-1,2,4-triazin-6(1H)-oneD-Amino-Acid OxidaseEnzyme InhibitorsSerineTriazinesd-Amino acid oxidased-SerineFlavoenzymePharmacokineticsSchizophrenia

Identifiers

PMID26965861
PMCPMC4816084
OpenAlexW2275142163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.